Biomarcadores para el diagnóstico, pronóstico y caracterización de la esclerosis sistémica.
Palabras clave:
Anticuerpos antinucleares, esclerodermia sistémica, biomarcadores, fibrosis, reumatología, proteínas de fase aguda.Resumen
Introducción: La esclerosis sistémica es una enfermedad caracterizada por una tríada clínica compuesta por fibrosis orgánica progresiva, disfunción endotelial y activación anormal del sistema inmunitario. Actualmente existen tres biomarcadores clásicos asociados a la patología, pero se buscan nuevos que sean útiles en el seguimiento, diagnóstico y pronóstico de la enfermedad. Objetivo: Analizar la utilidad de nuevos biomarcadores para el seguimiento, pronóstico, diagnóstico y caracterización clínica de la esclerosis sistémica. Métodos: Se realizó una búsqueda avanzada en PubMed, Embase, Google Scholar y Scopus, obteniéndose 50 artículos. Desarrollo del tema: Se caracterizaron nuevos autoanticuerpos, reactantes de fase aguda, marcadores celulares y proteínas séricas como potenciales biomarcadores de utilidad clínica en esta enfermedad. Conclusión: Se encontraron nuevos biomarcadores con valor clínico para el seguimiento, pronóstico, caracterización clínica y diagnóstico de la esclerosis sistémica.
Descargas
Referencias
1. Gargiulo MLÁ, Perez N, Khoury M, Buhl M, Suárez L, Sarano J,et al. Anti-RNA polymerase III antibodies in systemic sclerosis: Multicentric study from Argentina. Reumatol Clin (Engl Ed). 2022; 18(6):368-373. DOI: 10.1016/j.reumae.2021.02.003.
2. Motta F, Tonutti A, Isailovic N, Ceribelli A, Costanzo G, Rodolfi S,et al. Proteomic aptamer analysis reveals serum biomarkers associated with disease mechanisms and phenotypes of systemic sclerosis. Front Immunol. 2023; 14:1246777. DOI: 10.3389/fimmu.2023.1246777.
3. Reyes-Long S, Gutierrez M, Clavijo-Cornejo D, Alfaro-Rodríguez A, González-Sámano K, Cortes-Altamirano JL, et al. Subclinical Interstitial Lung Disease in Patients with Systemic Sclerosis. A Pilot Study on the Role of Ultrasound. Reumatol Clin (Engl Ed). 2021; 17(3):144-149. English, Spanish. DOI: 10.1016/j.reuma.2019.05.004.
4. Kim H, Cho SK, Kim JW, Jung SY, Jang EJ, Bae SC, et al. An increased disease burden of autoimmune inflammatory rheumatic diseases in Korea. Semin Arthritis Rheum. 2020; 50(3):526-533. DOI: 10.1016/j.semarthrit.2019.11.007.
5. Zhong L, Pope M, Shen Y, Hernandez JJ, Wu L. Prevalence and incidence of systemic sclerosis: A systematic review and meta-analysis. Int J Rheum Dis. 2019; 22(12):2096-2107. DOI: 10.1111/1756-185X.13716.
6. Tian J, Kang S, Zhang D, Huang Y, Zhao M, Gui X, Yao X,et al. Global, regional, and national incidence and prevalence of systemic sclerosis. Clin Immunol. 2023; 248:109267. DOI: 10.1016/j.clim.2023.109267.
7. van den Hoogen F, Khanna D, Fransen J, Johnson SR, Baron M, Tyndall A, et al. 2013 classification criteria for systemic sclerosis: an American college of rheumatology/European league against rheumatism collaborative initiative. Ann Rheum Dis. 2013; 72(11):1747-55. DOI: 10.1136/annrheumdis-2013-204424.
8. Low AH, Wong S, Thumboo J, Ng SC, Lim JY, Ng X, Earnest A, Fong KY. Evaluation of a new multi-parallel line immunoassay for systemic sclerosis-associated antibodies in an Asian population. Rheumatology (Oxford). 2012; 51(8):1465-70. DOI: 10.1093/rheumatology/kes055.
9. Stochmal A, Czuwara J, Trojanowska M, Rudnicka L. Antinuclear Antibodies in Systemic Sclerosis: an Update. Clin Rev Allergy Immunol. 2020 ;58(1):40-51. DOI: 10.1007/s12016-018-8718-8.
10. Liaskos C, Marou E, Simopoulou T, Barmakoudi M, Efthymiou G, Scheper T, et al. Disease-related autoantibody profile in patients with systemic sclerosis. Autoimmunity. 2017; 50(7):414-421. DOI: 10.1080/08916934.2017.1357699.
11. Liberal R, Grant CR, Sakkas L, Bizzaro N, Bogdanos DP. Diagnostic and clinical significance of anti-centromere antibodies in primary biliary cirrhosis. Clin Res Hepatol Gastroenterol. 2013; 37(6):572-85. DOI: 10.1016/j.clinre.2013.04.005.
12. Wang J, Assassi S, Guo G, Tu W, Wu W, Yang L, et al. Clinical and serological features of systemic sclerosis in a Chinese cohort. Clin Rheumatol. 2013 ;32(5):617-21. DOI: 10.1007/s10067-012-2145-7.
13. Volkmann ER, Andréasson K, Smith V. Systemic sclerosis. Lancet. 2023 28; 401(10373):304-318. DOI: 10.1016/S0140-6736(22)01692-0.
14. Hamaguchi Y, Kodera M, Matsushita T, Hasegawa M, Inaba Y, Usuda T,et al. Clinical and immunologic predictors of scleroderma renal crisis in Japanese systemic sclerosis patients with anti-RNA polymerase III autoantibodies. Arthritis Rheumatol. 2015; 67(4):1045-52. DOI: 10.1002/art.38994.
15. Tsukamoto M, Suzuki K, Takeuchi T. Initial presentation determines clinical entity in patients with anti-centromere antibody positivity. Int J Rheum Dis. 2019; 22(1):103-107. DOI: 10.1111/1756-185X.13439.
16. Gunn J, Pauling JD, McHugh NJ. Impact of anti-centromere antibodies on pulmonary function test results in patients with systemic sclerosis without established or suspected pulmonary disease. Clin Rheumatol. 2014; 33(6):869-71. DOI: 10.1007/s10067-014-2616-0.
17. Utsunomiya A, Hasegawa M, Oyama N, Asano Y, Endo H, Fujimoto M, . Clinical course of Japanese patients with early systemic sclerosis: A multicenter, prospective, observational study. Mod Rheumatol. 2021; 31(1):162-170. DOI: 10.1080/14397595.2020.1751408.
18. Yang C, Tang S, Zhu D, Ding Y, Qiao J. Classical Disease-Specific Autoantibodies in Systemic Sclerosis: Clinical Features, Gene Susceptibility, and Disease Stratification. Front Med (Lausanne). 2020; 7:587773. DOI: 10.3389/fmed.2020.587773.
19. Pisetsky DS. Annals of the Rheumatic Diseases collection on autoantibodies in the rheumatic diseases: new insights into pathogenesis and the development of novel biomarkers. Ann Rheum Dis. 2023; 82(10):1243-1247. DOI: 10.1136/ard-2023-224692.
20. Hu CJ, Song G, Huang W, Liu GZ, Deng CW, Zeng HP, et al. Identification of new autoantigens for primary biliary cirrhosis using human proteome microarrays. Mol Cell Proteomics. 2012; 11(9):669-80. DOI: 10.1074/mcp.M111.015529.
21. Sengupta S, Kennemer A, Patrick K, Tsichlis P, Guerau-de-Arellano M. Protein Arginine Methyltransferase 5 in T Lymphocyte Biology. Trends Immunol. 2020; 41(10):918-931. DOI: 10.1016/j.it.2020.08.007.
22. Caza TN, Storey AJ, Hassen SI, Herzog C, Edmondson RD, Arthur JM, Kenan DJ, Larsen CP. Discovery of seven novel putative antigens in membranous nephropathy and membranous lupus nephritis identified by mass spectrometry. Kidney Int. 2023; 103(3):593-606. DOI: 10.1016/j.kint.2023.01.001.
23. Liang M, Wang L, Tian X, Wang K, Zhu X, Huang L, et al. Identification and validation of anti-protein arginine methyltransferase 5 (PRMT5) antibody as a novel biomarker for systemic sclerosis (SSc). Ann Rheum Dis. 2024; 83(9):1144-1155. DOI: 10.1136/ard-2024-225596.
24. Sjöberg R, Mattsson C, Andersson E, Hellström C, Uhlen M, Schwenk JM, et al. Exploration of high-density protein microarrays for antibody validation and autoimmunity profiling. N Biotechnol. 2016; 33(5 Pt A):582-92. DOI: 10.1016/j.nbt.2015.09.002.
25. Liu C, Song G, Yan S, He Y, Hu C, Hou Y, et al. Identification of Anti-SNRPA as a Novel Serological Biomarker for Systemic Sclerosis Diagnosis. J Proteome Res. 2023; 22(10):3254-3263. DOI: 10.1021/acs.jproteome.3c00268.
26. Karasawa R, Tamaki M, Sato T, Tanaka M, Nawa M, Yudoh K, et al. Multiple target autoantigens on endothelial cells identified in juvenile dermatomyositis using proteomics. Rheumatology (Oxford). 2018; 57(4):671-676. DOI: 10.1093/rheumatology/kex468.
27. Medsger TA Jr, Bombardieri S, Czirjak L, Scorza R, Della Rossa A, Bencivelli W. Assessment of disease severity and prognosis. Clin Exp Rheumatol. 2003; 21(3 Suppl 29):S42-6. PMID: 12889222.
28. Hudson M, Steele R; Canadian Scleroderma Research Group (CSRG); Baron M. Update on indices of disease activity in systemic sclerosis. Semin Arthritis Rheum. 2007; 37(2):93-8. DOI: 10.1016/j.semarthrit.2007.01.005.
29. Ross L, Stevens W, Rabusa C, Wilson M, Ferdowsi N, Walker J, et al. The role of inflammatory markers in assessment of disease activity in systemic sclerosis. Clin Exp Rheumatol. 2018; 36 Suppl 113(4):126-134.
30. Vonk MC, Walker UA, Volkmann ER, Kreuter M, Johnson SR, Allanore Y. Natural variability in the disease course of SSc-ILD: implications for treatment. Eur Respir Rev. 2021; 30(159):200340. DOI: 10.1183/16000617.0340-2020.
31. Stifano G, Sornasse T, Rice LM, Na L, Chen-Harris H, Khanna et al. Skin Gene Expression Is Prognostic for the Trajectory of Skin Disease in Patients With Diffuse Cutaneous Systemic Sclerosis. Arthritis Rheumatol. 2018; 70(6):912-919. DOI: 10.1002/art.40455.
32. Xu X, Ramanujam M, Visvanathan S, Assassi S, Liu Z, Li L. Transcriptional insights into pathogenesis of cutaneous systemic sclerosis using pathway driven meta-analysis assisted by machine learning methods. PLoS One. 2020; 15(11):e0242863. DOI: 10.1371/journal.pone.0242863.
33. Berkowitz JS, Tabib T, Xiao H, Sadej GM, Khanna D, Fuschiotti P, et al. Cell Type-Specific Biomarkers of Systemic Sclerosis Disease Severity Capture Cell-Intrinsic and Cell-Extrinsic Circuits. Arthritis Rheumatol. 2023; 75(10):1819-1830. DOI: 10.1002/art.42536.
34. Apostolidis SA, Stifano G, Tabib T, Rice LM, Morse CM, Kahaleh B,et al. Single Cell RNA Sequencing Identifies HSPG2 and APLNR as Markers of Endothelial Cell Injury in Systemic Sclerosis Skin. Front Immunol. 2018; 9:2191. DOI: 10.3389/fimmu.2018.02191. P
35. Tabib T, Huang M, Morse N, Papazoglou A, Behera R, Jia M, et al. Myofibroblast transcriptome indicates SFRP2hi fibroblast progenitors in systemic sclerosis skin. Nat Commun. 2021; 12(1):4384. DOI: 10.1038/s41467-021-24607-6.
36. Xue D, Tabib T, Morse C, Yang Y, Domsic RT, Khanna D, et al. Expansion of Fcγ Receptor IIIa-Positive Macrophages, Ficolin 1-Positive Monocyte-Derived Dendritic Cells, and Plasmacytoid Dendritic Cells Associated With Severe Skin Disease in Systemic Sclerosis. Arthritis Rheumatol. 2022; 74(2):329-341. DOI: 10.1002/art.41813.
37. Xu Z, Cheng C, Kong R, Liu Y, Wang S, Ma Y, et al. S100A8 and S100A9, both transcriptionally regulated by PU.1, promote epithelial-mesenchymal transformation (EMT) and invasive growth of dermal keratinocytes during scar formation post burn. Aging (Albany NY). 2021; 13(11):15523-15537. DOI: 10.18632/aging.203112.
38. Nazari B, Rice LM, Stifano G, Barron AM, Wang YM, et al. Altered Dermal Fibroblasts in Systemic Sclerosis Display Podoplanin and CD90. Am J Pathol. 2016; 186(10):2650-64. DOI: 10.1016/j.ajpath.2016.06.020.
39. Pendergrass SA, Lemaire R, Francis IP, Mahoney JM, Lafyatis R, Whitfield ML. Intrinsic gene expression subsets of diffuse cutaneous systemic sclerosis are stable in serial skin biopsies. J Invest Dermatol. 2012; 132(5):1363-73. DOI: 10.1038/jid.2011.472.
40. Carvalheiro T, Lopes AP, van der Kroef M, Malvar-Fernandez B, Rafael-Vidal C, Hinrichs AC, et al. Angiopoietin-2 Promotes Inflammatory Activation in Monocytes of Systemic Sclerosis Patients. Int J Mol Sci. 2020; 21(24):9544. DOI: 10.3390/ijms21249544.
41. Zenewicz LA. IL-22 Binding Protein (IL-22BP) in the Regulation of IL-22 Biology. Front Immunol. 2021 Nov 16;12:766586. DOI: 10.3389/fimmu.2021.766586.
42. Whittington HA, Armstrong L, Uppington KM, Millar AB. Interleukin-22: a potential immunomodulatory molecule in the lung. Am J Respir Cell Mol Biol. 2004 31(2):220-6. DOI: 10.1165/rcmb.2003-0285OC.
43. Bennett D, Salvini M, Fui A, Cillis G, Cameli P, Mazzei MA, et al. Calgranulin B and KL-6 in Bronchoalveolar Lavage of Patients with IPF and NSIP. Inflammation. 2019; 42(2):463-470. DOI: 10.1007/s10753-018-00955-2.
44. Cavazzana I, Vojinovic T, Airo’ P, Fredi M, Ceribelli A, Pedretti E,et al. Systemic Sclerosis-Specific Antibodies: Novel and Classical Biomarkers. Clin Rev Allergy Immunol. 2023; 64(3):412-430. DOI: 10.1007/s12016-022-08946-w.
45. Coghlan JG, Denton CP, Grünig E, Bonderman D, Distler O, Khanna D,et al; DETECT study group. Evidence-based detection of pulmonary arterial hypertension in systemic sclerosis: the DETECT study. Ann Rheum Dis. 2014; 73(7):1340-9. DOI: 10.1136/annrheumdis-2013-203301.
46. Watanabe S, Kase K, Saeki K, Ohkura N, Murata A, Waseda Y, et al. Kinetic changes in serum KL-6 levels predict disease progression in patients with systemic sclerosis-associated interstitial lung disease. Respir Med. 2022; 191:106689. DOI: 10.1016/j.rmed.2021.106689.
47. Jee AS, Stewart I, Youssef P, Adelstein S, Lai D, Hua S, et al; Australian Scleroderma Cohort Study, Australian Scleroderma Interest Group, Australian Idiopathic Pulmonary Fibrosis Registry, and associated investigators. A Composite Serum Biomarker Index for the Diagnosis of Systemic Sclerosis-Associated Interstitial Lung Disease: A Multicenter, Observational Cohort Study. Arthritis Rheumatol. 2023; 75(8):1424-1433. DOI: 10.1002/art.42491.
48. Wermuth PJ, Piera-Velazquez S, Jimenez SA. Identification of novel systemic sclerosis biomarkers employing aptamer proteomic analysis. Rheumatology (Oxford). 2018 ; 57(10):1698-1706. DOI: 10.1093/rheumatology/kex404.
49. Parker MJS, Jee AS, Hansen D, Proudman S, Youssef P, Kenna TJ, et al. Multiple serum biomarkers associate with mortality and interstitial lung disease progression in systemic sclerosis. Rheumatology (Oxford). 2024; 63(11):2981-2988. DOI: 10.1093/rheumatology/keae110
50. Wermuth PJ, Piera-Velazquez S, Rosenbloom J, Jimenez SA. Existing and novel biomarkers for precision medicine in systemic sclerosis. Nat Rev Rheumatol. 2018; 14(7):421-432. DOI: 10.1038/s41584-018-0021-9.
Descargas
Publicado
Número
Sección
Licencia
Derechos de autor 2026 Maximiliano Izquierdo-Piedrahita
Esta obra está bajo una licencia internacional Creative Commons Atribución 4.0.
La Revista Salutem Scientia Spiritus usa la licencia Creative Commons de Atribución – No comercial – Sin derivar: Los textos de la revista son posibles de ser descargados en versión PDF siempre que sea reconocida la autoría y el texto no tenga modificaciones de ningún tipo.
